#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout

UniQure may be getting all the ASH attention for hemophilia B, but Pfizer is trying to carve out a niche in hemophilia A.

The pharma giant and its gene editing partner Sangamo announced long-term data from their Phase I/II gene therapy, showing that all five patients that have been on the therapy have seen “sustained factor VIII levels.” The median factor VIII levels were 56.9%, with the average coming to 70.4%.

No patient required infusions or suffered a bleedin